Parliament is moved to reconsider the fate of cannabinoid patients as GW Pharma faces uncertain future in epilepsy cannabinoid market
The 4th annual Emerald Conference brought researchers and scientists from around the world to share their findings in San Diego last week.
The battle to approve Israeli medical cannabis for export has hit a snag as Israel’s president bows to Trump’s request to halt the impending trade.
In the first part of this series, we’ll identify the key aspects of a hazard analysis.
Secretary of State Dennis Richardson released an audit of the OLCC, detailing inadequate tracking systems, inspections, security risks and regulatory oversight.
Andre Schultz calls for decriminalization and states that recreational reform is on the horizon.
In an email sent to licensees, WSLCB Deputy Director Peter Antolin mentioned a security incident as the culprit for the state’s tracking system disruption.
The move to brand a targeted cannabinoid treatment for refractory epilepsy is a unique development in an EU market focused on generics.
The addition will further expand IPC’s event capabilities.
The rescinding of the Cole memo does not suggest the sky is about to fall for the U.S. cannabis industry, but it should be a wake-up call for those who have been playing fast and loose with their business operations.
